Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Issued: 2019-2025

Historic Shares Issued for C4 Therapeutics (CCCC) over the last 4 years, with Sep 2025 value amounting to $107,000.

  • C4 Therapeutics' Shares Issued rose 723.08% to $107,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $366,000, marking a year-over-year decrease of 45.29%. This contributed to the annual value of $778,000 for FY2024, which is 1241.38% up from last year.
  • As of Q3 2025, C4 Therapeutics' Shares Issued stood at $107,000, which was down 3.60% from $111,000 recorded in Q4 2024.
  • C4 Therapeutics' Shares Issued's 5-year high stood at $873,000 during Q3 2021, with a 5-year trough of $2,000 in Q2 2023.
  • Over the past 3 years, C4 Therapeutics' median Shares Issued value was $107,000 (recorded in 2025), while the average stood at $134,714.
  • Per our database at Business Quant, C4 Therapeutics' Shares Issued crashed by 99.61% in 2021 and then soared by 6,650.00% in 2024.
  • Over the past 5 years, C4 Therapeutics' Shares Issued (Quarterly) stood at $752,000 in 2021, then slumped by 93.75% to $47,000 in 2022, then plummeted by 99.23% to $2,000 in 2023, then skyrocketed by 6,650.00% to $111,000 in 2024, then spiked by 723.08% to $107,000 in 2025.
  • Its Shares Issued stands at $107,000 for Q3 2025, versus $111,000 for Q4 2024 and $13,000 for Q3 2024.